Atlanta, GA
Stem Cell Therapy clinics in Atlanta
Atlanta supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Emory University Hospital, Piedmont, and Northside, and stem cell practice in the area spans Buckhead, Midtown, and Sandy Springs. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Georgia regulates physician practice through the Georgia Composite Medical Board. There is no state-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. The FDA has issued warning letters to Georgia-based stem cell operators marketing unapproved biologics. The 24 Atlanta clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Georgia Composite Medical Board licensure checks.
Inspire Wellness & Aesthetics
- PRP Therapy
- Shockwave Therapy
- IV Therapy
- Laser Therapy (LLLT)
- Hyperbaric Oxygen Therapy (HBOT)
Gentle Giant Care
- PRP Therapy
- Shockwave Therapy
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Acne Treatment
Regenerative Orthopaedics and Spine Institute
- PRP Therapy
- Arthritis Treatment
- Peptide Therapy
- Testosterone Replacement Therapy (TRT)
- Stem Cell Therapy
Life Balance Pain Care
- PRP Therapy
- Arthritis Treatment
- Migraine Treatment
- Stem Cell Therapy
Paragon Sports Medicine
- PRP Therapy
- IV Therapy
- Arthritis Treatment
- Peptide Therapy
- Hormone Replacement Therapy (HRT)
Pravida Health
- PRP Therapy
- IV Therapy
- Laser Therapy (LLLT)
- Hyperbaric Oxygen Therapy (HBOT)
- Arthritis Treatment
MD on staff
Mobile Aesthetics & Wellness
- PRP Therapy
- IV Therapy
- Laser Therapy (LLLT)
- IV Hydration
- Peptide Therapy
Regulatory context
A note on Georgia's stem cell therapy rules.
Georgia cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed for orthopedic, neurologic, autoimmune, and longevity indications in Georgia are Section 351 biologics that lack FDA approval. The FDA's enforcement discretion period ended in May 2021, so clinics in Georgia operating outside Section 361 face direct federal exposure.
-
Georgia Medical Practice Act, OCGA Title 43, Chapter 34
Establishes physician licensure and discipline through the Georgia Composite Medical Board. -
Georgia Pharmacy Practice Act, OCGA Title 26, Chapter 4
Regulates compounding pharmacies and aligns with federal 503A and 503B rules for biologic preparation. -
Georgia Fair Business Practices Act, OCGA Title 10, Chapter 1
Empowers the Attorney General to pursue deceptive trade practice claims against providers making unsupported clinical claims.
The FDA has issued warning letters and untitled letters to Georgia clinics offering stem cell and exosome therapies. The Georgia Composite Medical Board has authority to discipline physicians for unprofessional conduct including misleading regenerative medicine advertising. The Georgia Attorney General's Consumer Protection Division has used the Fair Business Practices Act to pursue deceptive health marketing. Georgia has not produced a federal injunction comparable to the Florida US Stem Cell case, but the state's busy Atlanta market draws federal attention. Clinics that label products as homologous-use Section 361 HCT/Ps face inspection and labeling scrutiny.